UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 18, 2017

 

GREY CLOAK TECH INC.

(Exact name of registrant as specified in its charter)

 

Nevada

(State or other

jurisdiction of incorporation)

 

333-202542

(Commission

File Number)

 

47-2594704

(I.R.S. Employer

Identification No.)

         

10300 W. Charleston

Las Vegas, NV 89135

(Address of principal executive offices) (zip code)

         

(702) 201-6450

(Registrant’s telephone number, including area code)

         
         
 (Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 
 
 

Section 8 – Other Events

 

Item 8.01 Other Events

 

On September 18, 2017 we executed a Letter of Intent with Eqova Life Sciences, a medically-focused CBD company. The Letter of Intent is non-binding, but the parties expect to consummate the transaction as soon as reasonably practicable.

 

A press release issued on September 19, 2017 announcing the Letter of Intent is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01 Financial Statements and Exhibits.

 

(d)       Exhibits

 

99.1   Press release of Premier Biomedical, Inc. dated September 19, 2017.

- 1 -

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  Grey Cloak Tech Inc.
   
   
Dated: October 4, 2017  /s/ William Bossung
  By: William Bossung
  Its: Chief Financial Officer and Secretary

 

 

- 2 -

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press release of Premier Biomedical, Inc. dated September 19, 2017.